ArticleThrombosis research2020
Pulmonary embolism: A complication of COVID 19 infection.
Article in Thrombosis research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Article
- Article
- CTPA ordering trends in local emergency departments: are they increasing and did they increase as a result of COVID-19?Emergency radiology · 2023Article
- Tracheostomy insertion in COVID-19: insertion practice and factors leading to unplanned tube exchange.Journal of thoracic disease · 2023Article
- TIMELESS is a key gene mediating thrombogenesis in COVID-19 and antiphospholipid syndrome.Scientific reports · 2022Article
- Circulating cell clusters aggravate the hemorheological abnormalities in COVID-19.Biophysical journal · 2022Article
- Venous thromboembolism in COVID-19: A meta-summary of cases.Saudi medical journal · 2022Article
- Hereditary Thrombophilia in the Era of COVID-19.Healthcare (Basel, Switzerland) · 2022Review
- Role of LL-37 in thrombotic complications in patients with COVID-19.Cellular and molecular life sciences : CMLS · 2022Article
- Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Incidence of thrombotic complications in COVID-19 : On behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium.Journal of thrombosis and thrombolysis · 2021Review
- Mechanisms of Immunothrombosis by SARS-CoV-2.Biomolecules · 2021Review
- Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents.Metabolites · 2021Review
- A Review of Venous Thromboembolism Phenomena in COVID-19 Patients.Current problems in cardiology · 2021Review
- Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study.Thrombosis research · 2021Article
- Cardiopulmonary Resuscitation Outcomes of Patients with COVID-19; a One-Year Survey.Archives of academic emergency medicine · 2021Article
- Unexpected high frequency of early mortality in COVID-19: a single-centre experience during the first wave of the pandemic.Internal medicine journal · 2021Article
- Case Report: An Unusual Case of Biventricular Thrombosis in a COVID-19 Patient With Ischemic Dilated Cardiomyopathy: Assessment of Mass Mobility and Embolic Risk by Tissue Doppler Imaging.Frontiers in cardiovascular medicine · 2021Article
- COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past.Clinical cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus Disease 2019 (COVID 19) has been reported in almost every country in the world. Although a large proportion of infected individuals develop only mild symptoms or are asymptomatic, the spectrum of the disease among others has been widely variable in severity. Additionally, many infected individuals were found to have coagulation markers abnormalities. This is especially true among those progressing to severe pneumonia and multi-organ failure. While the incidence of venous thromboembolic (VTE) disease has been recently noted to be elevated among critically ill patients, the incidence among ambulatory and non-critically ill patients is not yet clearly defined. Herein, we present six patients who didn't have any hypercoagulable risk factors yet presented with pulmonary embolism in association with COVID 19 infection. Furthermore, we discuss the possible underlying mechanisms of hypercoagulability and highlight the possibility of underdiagnosing pulmonary embolism in the setting of overlapping symptoms, decreased utilization of imaging secondary to associated risks, and increased turnover times. In addition, we emphasize the role of extended thromboprophylaxis in discharged patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.